Elevance Health Inc. (ELV) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$369.07
Price Target
$382.38
Target Range
$331.00 — $425.00
Analyst Rating
Buy
Forward P/E13.8x
Trailing P/E14.7x
Forward PEG1.99
Implied Growth+12.5%
Median Target$391.00
Analyst Spread24.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$331
-10.3%
Consensus
$382
+3.6%
Bull Case
$425
+15.2%
Valuation Model TargetsConfidence: 80/100
Bear$397
Base$486
Bull$896
ELV Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Elevance Health Inc. (ELV) has a Wall Street consensus price target of $382.38, based on estimates from 37 covering analysts. With the stock currently trading at $369.07, this represents a potential upside of +3.6%. The company has a market capitalization of $80.15B.
Analyst price targets range from a low of $331.00 to a high of $425.00, representing a 25% spread in expectations. The median target of $391.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ELV trades at a trailing P/E of 14.7x and forward P/E of 13.8x. The forward PEG ratio of 1.99 indicates reasonable valuation for growth. Analysts expect EPS to grow +12.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $486.45, with bear and bull scenarios of $396.69 and $896.14 respectively. Model confidence stands at 80/100, indicating high predictability in the company's fundamentals.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+20.4%
Avg Forward P/E39.1x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 UNHUnitedHealth Group Incorporated | $330.3B | $363.87 | $385.43 | +5.9% | Buy | 19.9x | 52 |
 CVSCVS Health Corporation | $102.6B | $80.69 | $95.20 | +18.0% | Buy | 11.3x | 41 |
 CICigna Corporation | $72.7B | $275.66 | $328.00 | +19.0% | Buy | 9.1x | 39 |
 HUMHumana Inc. | $28.8B | $239.53 | $246.00 | +2.7% | Hold | 26.8x | 44 |
 CNCCentene Corporation | $26.2B | $52.97 | $51.00 | -3.7% | Buy | 15.7x | 43 |
 MOHMolina Healthcare, Inc. | $10.0B | $192.17 | $166.09 | -13.6% | Buy | 37.3x | 38 |
 OSCROscar Health, Inc. | $4.7B | $17.94 | $16.75 | -6.6% | Hold | 29.8x | 11 |
 CLOVClover Health Investments, Corp. | $1.3B | $2.61 | $3.33 | +27.6% | Hold | 61.0x | 9 |
 ALHCAlignment Healthcare, Inc. | $3.7B | $18.30 | $24.83 | +35.7% | Buy | 141.3x | 16 |
 BHVNBiohaven Ltd. | $1.3B | $9.71 | $21.29 | +119.3% | Buy | — | 25 |
Upside Potential Comparison
BHVNALHCCLOVCICVSUNHHUMCNCFull ELV Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ELV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELV — Frequently Asked Questions
Quick answers to the most common questions about buying ELV stock.
What is the ELV stock price target for 2026?
The consensus price target for ELV is $382.38, close to the current price of $369.07 (3.6% implied move). Based on 37 analyst estimates, the stock appears fairly valued near current levels.
Is ELV a buy, sell, or hold?
ELV has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $382.38 implies 3.6% upside from current levels.
Is ELV stock overvalued or undervalued?
With a forward P/E of 13.7855x, ELV trades at a relatively low valuation. The consensus target of $382.38 implies 3.6% appreciation, suggesting the market may be pricing in risks.
How high can ELV stock go?
The most bullish Wall Street analyst has a price target of $425 for ELV, while the most conservative target is $331. The consensus of $382.38 represents the median expectation. Our quantitative valuation model projects a bull case target of $896 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover ELV stock?
ELV is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 11 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ELV stock forecast?
The 12-month ELV stock forecast based on 37 Wall Street analysts shows a consensus price target of $382.38, with estimates ranging from $331 (bear case) to $425 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $486, with bear/bull scenarios of $397/$896.
What is ELV's fair value based on fundamentals?
Our quantitative valuation model calculates ELV's fair value at $486 (base case), with a bear case of $397 and bull case of $896. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 80/100.
What is ELV's forward P/E ratio?
ELV trades at a forward P/E ratio of 13.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ELV stock?
ELV appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $382.38 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ELV price targets vary so much?
ELV analyst price targets range from $331 to $425, a 25% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $382.38 consensus represents the middle ground. Our model's $397-$896 range provides an independent fundamental perspective.